Mustafa DUMAN, Orhan UZUN, Hilmi BOZKURT, Tolga ÖLMEZ, Özlem Zeliha SERT, Esin KAPLAN, Emre ARAY, Rabia KOKSAL, Erdal POLAT

Comparison of first-line eradication therapy protocols for Helicobacter pylori in regions with high clarithromycin resistance

Aim: First-line eradication therapy protocols for Helicobacter pylori infection and their success rates still prove to be matter of interestfor researchers. The aim of this study was to examine retrospectively eradication therapy protocols used in patients infected with H.pylori in our region with high resistance to clarithromycin, compare success rates and determine the factors affecting success rates.Material and Methods: Eradication therapies for dyspeptic patients who were found to be Helicobacter pylori positive as revealed byupper gastrointestinal endoscopy and biopsy results and success rates attained in the microscopic examination of stool in the 4thweek after the therapy were analyzed. Group 1 (legacy triple therapy): clarithromycin 500 mg film-coated tablet 2x1, lansoprazole 30mg capsule 2x1, amoxicillin 1000 mg tablet 2x1, 14-day therapy period; Group 2 (bismuth-free quadruple therapy): clarithromycin500 mg film tablet 2x1, rabeprazole 20 mg tablet 2*1, amoxicillin 1000 mg tablet 2x1, metronidazole 500mg 2x1 tablet, 14-daytherapy period; Group 3 (bismuthal quadruple therapy): bismuth subsalicylate 262 mg tablet 2x2, metronidazole 500 mg tablet 3x1,tetracycline 500 mg capsule 3x1, pantoprazole 40mg tablet 2x1, 10-day therapy period.Results: Data of 168 patients were analyzed. The patients were divided into Group 1 (classical therapy) with 80 patients, Group 2(bismuth-free quadruple therapy) with 46 patients and Group 3 (bismuthal quadruple therapy) with 42 patients. Eradication successrates were as follows: Group 1 (80%), Group 2 (80.4%) and Group 3 (83.3%).Conclusion: Antibiotic resistance is the sole reason for the low success rate in eradication therapy for Helicobacter pylori.In regions with high clarithromycin resistance bismuth-free quadruple therapy can be employed as an alternative. In regions withmetronidazole resistance in addition to clarithromycin resistance bismuthal therapy protocols can be employed.

PDF

___

1. Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust 2016;204:376-80.
2. Alakkari A, Zullo A, O’Connor HJ. Helicobacter pylori and nonmalignant diseases. Helicobacter 2011;16:33-7.
3. Chey WD, Wong BC. American college of gastroenterology guideline on the management of helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
4. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
5. O’Connor A, Lamarque D, Gisbert JP, et al. Treatment of helicobacter pylori infection 2017. Helicobacter 2017;22:1.
6. Martins GM, Sanches BS, Moretzsohn LD, et al. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban Brazilian population. Arq Gastroenterol 2016;53:113-7.
7. Ji Z, Han F, Meng F, et al. The association of age and antibiotic resistance of Helicobacter pylori: a study in Jiaxing City, Zhejiang Province, China. Medicine (Baltimore) 2016;95:e2831.
8. Hakemi Vala M, Eyvazi S, Goudarzi H.et al. Evaluation of clarithromycin resistance among Iranian Helicobacter pylori isolates by E-Test and real-time polymerase chain reaction methods. Jundishapur J Microbiol 2016;9:e29839.
9. Alsohaibani F, Al Ashgar H, Al Kahtani K, et al. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015;21:220-5.
10. Tongtawee T, Dechsukhum C, Matrakool L, et al. High prevalence of Helicobacter pylori resistance to clarithromycin: a hospital-based cross-sectional study in Nakhon Ratchasima Province, Northeast of Thailand. Asian Pac J Cancer Prev 2015;16:8281-5.
11. Malfertheiner P, Megraud F, O’Morain CA, et al. European helicobacter and microbiota study group and consensus panel. Management of Helicobacter pylori infection-the maastricht V/Florence Consensus Report. Gut 2017;66:6- 30.
12. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and metaanalysis of sequential therapy BMJ 2013;347:f4587.
13. Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015;48:278-84.
14. Kaya AD, Oztürk CE, Akcan Y. et al. Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis. Curr Ther Res Clin Exp 2007;68:151-60.
15. Onder G, Aydin A, Akarca U, et al. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007;41:747-50.
16. Zhang M. High antibiotic resistance rate: a difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol 2015;21:13432-7.
17. Tong YF, Lv J, Ying LY, et al. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance. World J Gastroenterol 2015;21:13073-9.
18. Chen YI, Fallone CA. A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: a Canadian study conducted in a ‘real world’ setting. Can J Gastroenterol Hepatol 2015;29:e7-10.
19. Haider RB, Brennan DE, Omorogbe J, et al. A randomizedcontrolled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol 2015;27:1265-9.
20. Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating Helicobacter pylori: randomized clinical trial of efficacy and safety. Clin Res Hepatol Gastroenterol 2016;40:124-31.
21. Songür Y, Senol A, Balkarli A, et al. Triple or quadruple tetracycline- based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009;338:50-3.
22. Zhang W, Chen Q, Liang X, Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015;64:1715-20.
23. Zhang M. High antibiotic resistance rate: a difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol 2015;21:13432-7.
24. Alboraie M, Saad M, Al-Ali J, et al.Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait. Arab J Gastroenterol 2015;16:131-5.
25. Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med 2015;30:801-7.
26. Fallone CA, Chiba N, Van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016;151:51-69.
27. Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol 2018;33:37-56.
28. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-39.
29. Liou JM, Chen CC, Fang YJ, et al. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and secondline treatment of Helicobacter pylori: a multicentre, noninferiority, randomized trial. J Antimicrob Chemother. 2018;73:2510-18.
30. Uygun A, Tüzün A, Yeflilova Z, ve ark. Helikobakter pilori eradikasyon tedavisinde 7 ve 14 günlük lansoprazol, klaritromisin, amoksisilin protokolünün karşılaştırılması . Akademik Gastroenteroloji Dergisi 2005;4:172-5.
31. Ozbalcı GS, Yürüker SS, Tarım İA, et al. First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic. Ulusal Cer Derg 2014;30:133-7.
32. García FM, Rey IB, Iglesia D, et al. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial. Helicobacter 2018;e12546.
33. Köksal AS, Onder FO, Torun S et al. Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance. Acta Gastroenterol Belg 2013;76:34-37.
34. DeFrancesco V, Pontone S, Bellesia A, et al. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. Dig Liver Dis 2018;50:139-141.
35. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, openlabel, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
36. Wang L, Lin Z, Chen S, et al. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. Clin Microbiol Infect 2017;23:391-5.